Eisenberg R S
University of Michigan Law School, Ann Arbor, MI 48109, USA.
Trends Biotechnol. 1996 Aug;14(8):302-7. doi: 10.1016/0167-7799(96)10040-8.
Controversy over intellectual property rights in the results of large-scale cDNA sequencing raises intriguing questions about the roles of the public and private sectors in genomics research, and about who stands to benefit (and who stands to lose) from the private appropriation of genomic information. While the US Patent and Trademark Office has rejected patent applications on cDNA fragments of unknown function from the National Institutes of Health, private firms have pursued three distinct strategies for exploiting unpatented cDNA sequence information: exclusive licensing, non-exclusive licensing and dedication to the public domain.
大规模cDNA测序结果的知识产权争议引发了一些耐人寻味的问题，涉及公共部门和私营部门在基因组学研究中的作用，以及谁将从基因组信息的私人占有中受益（谁将受损）。虽然美国专利商标局已驳回了美国国立卫生研究院关于功能未知的cDNA片段的专利申请，但私营公司采取了三种不同策略来利用未申请专利的cDNA序列信息：独家许可、非独家许可和奉献给公共领域。
